Think It's Too Late to Buy Novo Nordisk? Here's the Biggest Reason Why There's Still Time.

Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of GLP-1 obesity drugs. Front and center of this is Novo Nordisk (NYSE: NVO), the once-obscure Danish company that earned the first U.S. Food and Drug Administration (FDA) approval for such treatments with its Wegovy back in mid-2021.

Even though the stock is down notably from the peak price it hit last year, it's still doing far better than in the pre-approval days. Competitors are biting at its heels in the weight loss segment, however, so is there any chance it could ascend those lofty heights again?

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »

The great weight loss drug game

Novo Nordisk bears would be quick to point a paw at the company's so far sole competitor in the GLP-1 race, Eli Lilly.

The powerful pharmaceutical competitor is already a top name in obesity drugs with its Zepbound, approved for the indication in late 2023, and a drug that's already stolen much fire from Wegovy.

With the understandably hot popularity of such treatments in obesity-beset America, numerous other developers are racing to get obesity treatments to market. One of the more prominent of these is biotech Viking Therapeutics, which is putting an oral medication through clinical trials.

Expanding waistlines, exploding demand

Novo Nordisk shareholders shouldn't be worried about this. Many analysts are predicting an explosion in weight loss drug sales, on the back of persistently heavy demand.

One is Research and Markets, which last month forecast that the global market for these medications would balloon to nearly $105 billion in 2035, from an estimated tally of $12.8 billion this year. And that's not even one of the more bullish predictions out there.

An eight-fold (at least) expansion of the market within only a handful of years will benefit every maker of such drugs, no matter how aggressively they're trying to take market share. And the companies that will be particularly resilient will be the veterans; as Novo Nordisk was a first mover, it'll surely reap the benefits of the monster upsurge.

Should you invest $1,000 in Novo Nordisk right now?

Before you buy stock in Novo Nordisk, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $524,747!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $622,041!*

Now, it’s worth noting Stock Advisor’s total average return is 792% — a market-crushing outperformance compared to 153% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of April 21, 2025

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy.